Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatin
Journal of Magnetic Resonance Imaging, 05/03/2012
Chang YC et al. – Dynamic contrast–enhanced (DCE) magnetic resonance imaging (MRI) enables a functional analysis of the treatment response of nonsmall–cell lung cancer (NSCLC). MRI parametric histogram has the potential to predict early treatment response of combined bevacizumab, gemcitabine, and cisplatin.